Akshay Nair summarises a recent systematic review and meta-analysis of modifiable predictors of dementia in mild cognitive impairment. The meta-analysis finds that diabetes and the presence of any neuropsychiatric symptoms significantly predicted the conversion of mild cognitive impairment to dementia.
[read the full story...]
Anti-psychotic medications comprise between 30–50% of all psychotropics prescribed for people with learning disabilities. One of the potential side effects is metabolic syndrome (a group of risk factors that occur together and increase the risk for coronary artery disease, stroke and type 2 diabetes in people with learning disabilities who have been prescribed antipsychotic medication.) [read the full story…]
People with learning disabilities are often prescribed anti-psychotic medication, whether or not there has been a diagnosis of psychiatric disorder. There continues to be some concern about the evidence base to support this. The most recent Cochrane review which looked at the issue in relation to people with learning disabilities and schizophrenia found that there is [read the full story…]
Antipsychotics are frequently used in the treatment of people with learning disabilities, but little is published in the literature concerning their metabolic and endocrine side-effects. The researchers in this observational study set out to compare indices of obesity, glucose, lipids and prolactin between 138 people with learning disabilities who were treated with antipsychotic medications and [read the full story…]
Anti-psychotic medications comprise between 30–50% of all psychotropics prescribed for people with learning disabilities as reported in this WELD post: This study set out to explore metabolic syndrome (a group of risk factors that occur together and increase the risk for coronary artery disease, stroke and type 2 diabetes in people with learning disabilities who [read the full story…]
